. 2018 Dec 11:11:309-321.

doi: 10.2147/JAA.S178531. eCollection 2018.

Matched cohort study of therapeutic strategies to prevent preschool wheezing/asthma attacks

Collaborators, Affiliations

Collaborators

Respiratory Effectiveness Group:
Willem M C van Aalderen¹⁰, Clare S Murray¹¹, Wanda Phipatanakul¹², Samatha Sonnappa¹³, Teoh Oon Hoe¹⁴, Richard J Martin¹⁵, Alberto Papi¹⁶, Stanley J Szefler¹⁷, Derek Skinner¹⁸, R Brett McQueen¹⁹, Omar S Usmani²⁰

Affiliations

¹ Blizard Institute, Queen Mary University of London, London, UK, j.grigg@qmul.ac.uk.
² Respiratory Effectiveness Group, Cambridge, UK.
³ School of Medicine, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, UK.
⁴ Pulmonary Division, Cincinnati Children's Hospital Medical Center, and Department of Pediatrics, University of Cincinnati, Cincinnati, OH, USA.
⁵ Family Physician Airways Group of Canada, University of Toronto, Toronto, ON, Canada.
⁶ Department of Child Health, Royal Aberdeen Children's Hospital, University of Aberdeen, Aberdeen, UK.
⁷ Respiratory Medicine, Cochin Hospital Group, AP-HP, University of Paris Descartes (EA2511), Paris, France.
⁸ Observational and Pragmatic Research Institute Pte Ltd, Singapore, Singapore.
⁹ Academic Primary Care, University of Aberdeen, Aberdeen, UK.
¹⁰ Department of Pediatric Respiratory Medicine and Allergy, Emma Children’s Hospital AMC, Amsterdam, the Netherlands.
¹¹ Division of Infection, Immunity and Respiratory Medicine, Manchester Academic Health Science Centre, The University of Manchester, University Hospital of South Manchester, and Royal Manchester Children’s Hospital, Manchester, UK.
¹² Division of Allergy and Immunology, Boston Children’s Hospital, and Harvard Medical School, Boston, MA, USA.
¹³ Department of Respiratory Paediatrics, Rainbow Children’s Hospital, Bengaluru, India, and Observational and Pragmatic Research Institute Pte Ltd, Singapore, Singapore.
¹⁴ Department of Paediatrics, Respiratory Medicine Service, KK Women’s and Children’s Hospital, Singapore, Singapore.
¹⁵ Department of Medicine, National Jewish Health, and University of Colorado Denver, Denver, CO, USA.
¹⁶ Department of Respiratory Medicine, University Hospital S. Anna, Ferrara, Italy.
¹⁷ Breathing Institute, Children’s Hospital Colorado, University of Colorado School of Medicine, Aurora, CO, USA.
¹⁸ Optimum Patient Care, Cambridge, UK.
¹⁹ University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA.
²⁰ Airway Disease Section, National Heart and Lung Institute, Imperial College London, and Royal Brompton Hospital, London, UK.

PMID: 30588038
PMCID: PMC6294169
DOI: 10.2147/JAA.S178531

Matched cohort study of therapeutic strategies to prevent preschool wheezing/asthma attacks

Jonathan Grigg et al. J Asthma Allergy. 2018.

. 2018 Dec 11:11:309-321.

doi: 10.2147/JAA.S178531. eCollection 2018.

Authors

Collaborators

Respiratory Effectiveness Group:
Willem M C van Aalderen¹⁰, Clare S Murray¹¹, Wanda Phipatanakul¹², Samatha Sonnappa¹³, Teoh Oon Hoe¹⁴, Richard J Martin¹⁵, Alberto Papi¹⁶, Stanley J Szefler¹⁷, Derek Skinner¹⁸, R Brett McQueen¹⁹, Omar S Usmani²⁰

Affiliations

¹ Blizard Institute, Queen Mary University of London, London, UK, j.grigg@qmul.ac.uk.
² Respiratory Effectiveness Group, Cambridge, UK.
³ School of Medicine, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, UK.
⁴ Pulmonary Division, Cincinnati Children's Hospital Medical Center, and Department of Pediatrics, University of Cincinnati, Cincinnati, OH, USA.
⁵ Family Physician Airways Group of Canada, University of Toronto, Toronto, ON, Canada.
⁶ Department of Child Health, Royal Aberdeen Children's Hospital, University of Aberdeen, Aberdeen, UK.
⁷ Respiratory Medicine, Cochin Hospital Group, AP-HP, University of Paris Descartes (EA2511), Paris, France.
⁸ Observational and Pragmatic Research Institute Pte Ltd, Singapore, Singapore.
⁹ Academic Primary Care, University of Aberdeen, Aberdeen, UK.
¹⁰ Department of Pediatric Respiratory Medicine and Allergy, Emma Children’s Hospital AMC, Amsterdam, the Netherlands.
¹¹ Division of Infection, Immunity and Respiratory Medicine, Manchester Academic Health Science Centre, The University of Manchester, University Hospital of South Manchester, and Royal Manchester Children’s Hospital, Manchester, UK.
¹² Division of Allergy and Immunology, Boston Children’s Hospital, and Harvard Medical School, Boston, MA, USA.
¹³ Department of Respiratory Paediatrics, Rainbow Children’s Hospital, Bengaluru, India, and Observational and Pragmatic Research Institute Pte Ltd, Singapore, Singapore.
¹⁴ Department of Paediatrics, Respiratory Medicine Service, KK Women’s and Children’s Hospital, Singapore, Singapore.
¹⁵ Department of Medicine, National Jewish Health, and University of Colorado Denver, Denver, CO, USA.
¹⁶ Department of Respiratory Medicine, University Hospital S. Anna, Ferrara, Italy.
¹⁷ Breathing Institute, Children’s Hospital Colorado, University of Colorado School of Medicine, Aurora, CO, USA.
¹⁸ Optimum Patient Care, Cambridge, UK.
¹⁹ University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA.
²⁰ Airway Disease Section, National Heart and Lung Institute, Imperial College London, and Royal Brompton Hospital, London, UK.

PMID: 30588038
PMCID: PMC6294169
DOI: 10.2147/JAA.S178531

Abstract

Background: An inhaled corticosteroid (ICS) or leukotriene receptor antagonist (LTRA) may prevent wheezing/asthma attacks in preschoolers with recurrent wheeze when added to short-acting β-agonist (SABA).

Objective: The aim of this historical matched cohort study was to assess the effectiveness of these treatments for preventing wheezing/asthma attacks.

Methods: Electronic medical records from the Optimum Patient Care Research Database were used to characterize a UK preschool population (1-5 years old) with two or more episodes of wheezing during 1 baseline year before first prescription (index date) of ICS or LTRA, or repeat prescription of SABA. Children initiating ICS or LTRA on the index date were matched 1:4 to those prescribed only SABA for age, sex, year of index prescription, mean baseline SABA dose, baseline attacks, baseline antibiotic prescriptions, and eczema diagnosis. Wheezing/asthma attacks (defined as asthma-related emergency attendance, hospital admission, or acute oral corticosteroid prescription) during 1 outcome year were compared using conditional logistic regression.

Results: Matched ICS and SABA cohorts included 990 and 3,960 children, respectively (61% male; mean [SD] age 3.2 [1.3] years), and matched LTRA and SABA cohorts included 259 and 1,036 children, respectively (65% male; mean [SD] age 2.6 [1.2] years). We observed no significant difference between matched cohorts in the odds of a wheezing/asthma attack: ICS vs SABA, OR (95% CI) 1.01 (0.85-1.19) and LTRA vs SABA, OR (95% CI) 1.28 (0.96-1.72).

Conclusion: We found no evidence that initiation of ICS or LTRA therapy is associated with fewer attacks during 1 outcome year than SABA alone for a heterogeneous group of preschool children with recurrent wheeze in the real-life clinical setting.

Keywords: ICS particle size; electronic medical records; inhaled corticosteroids; leukotriene receptor antagonists; observational study; short-acting β-agonist.

PubMed Disclaimer

Conflict of interest statement

Disclosure JG has received honoraria from GSK and Vifor Pharmaceuticals for Advisory Board membership. AN is an employee of the Respiratory Effectiveness Group. TWG reports personal fees from American Board of Pediatrics/Pediatric Pulmonary Subboard, personal fees from Teva, personal fees from GSK, personal fees from Regeneron Pharmaceuticals, grants from the National Institutes of Health (NIH), other from UpTo-Date, personal fees from Merck, personal fees from Sanofi, personal fees from Novartis, and personal fees from Aviragen. AK reports board membership with Aerocrine, AstraZeneca, Boehringer Ingelheim, Novartis, and Teva Pharmaceuticals, consultancy agreements with AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Mylan, Novartis, Pfizer, Teva Pharmaceuticals, and Johsnson and Johnson, Purdue, grants and unrestricted funding for investigator-initiated studies from Novartis, payment for lectures/speaking engagements from AstraZeneca, Boehringer Ingelheim, Mylan, Merck, Novartis, Pfizer, Purdue Pharmaceuticals, and payment for the development of educational materials from Benton Dickinson. NR has received over the past 3 years fees for speaking, organising education, participation in advisory boards or consulting from 3M, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, MSD-Chibret, Mundipharma, Novartis, Pfizer, Sanofi, Sandoz, Teva, and Zambon, and research grants from Novartis, Boehringer Ingelheim, and Pfizer. EVH is a consultant to the Observational and Pragmatic Research Institute Pte Ltd (Singapore) and has received payment for medical writing work from Merck. DBP has board membership with Aerocrine, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan, Mundipharma, Napp, Novartis, and Teva Pharmaceuticals, reports consultancy agreements with Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mylan, Mundipharma, Napp, Novartis, Pfizer, Teva Pharmaceuticals, and Theravance, grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) from Aerocrine, AKL Research and Development Ltd, AstraZeneca, Boehringer Ingelheim, British Lung Foundation, Chiesi, Mylan, Mundipharma, Napp, Novartis, Pfizer, Respiratory Effectiveness Group, Teva Pharmaceuticals, Theravance, UK National Health Service, and Zentiva, payment for lectures/speaking engagements from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Mylan, Merck, Mundipharma, Novartis, Pfizer, Skyepharma, and Teva Pharmaceuticals, payment for manuscript preparation from Mundipharma and Teva Pharmaceuticals, payment for the development of educational materials from Mundipharma and Novartis, payment for travel/accommodation/meeting expenses from Aerocrine, AstraZeneca, Boehringer Ingelheim, Mundipharma, Napp, Novartis, and Teva Pharmaceuticals, funding for patient enrollment or completion of research from Chiesi, Novartis, Teva Pharmaceuticals, and Zentiva, and stock/stock options from AKL Research and Development Ltd which produces phytopharmaceuticals, owns 74% of the social enterprise Optimum Patient Care Ltd (Australia, Singapore, and UK) and 74% of Observational and Pragmatic Research Institute Pte Ltd (Singapore), and is a peer reviewer for grant committees of the Efficacy and Mechanism Evaluation programme and Health Technology Assessment. The other authors report no conflicts of interest in this work.

Figures

**Figure 1**
Study schematic. **Notes:** The eligibility criterion of two or more OCS prescriptions (at different points in time) could be for any combination of OCS, with or without concomitant SABA, with accompanying code for a lower respiratory complaint. ^aPrescribed therapy could change during the outcome year after the index date. **Abbreviations:** ICS, inhaled corticosteroid; LTRA, leukotriene receptor antagonist; OCS, oral corticosteroid; SABA, short-acting β-agonist.

**Figure 2**
Forest plot depicting OR (95% CIs) of wheezing/asthma attack for the four matched cohort comparisons. **Notes:** The reference cohort (attack odds =1.0) is listed second. EF: EF particle; fine: fine particle. **Abbreviations:** EF, extrafine; ICS, inhaled corticosteroid; LTRA, leukotriene receptor antagonist; SABA, short-acting β-agonist.

**Figure 3**
Percentage of children with one or more wheezing/asthma attacks during the baseline year (before the first prescription of ICS, LTRA, or repeat SABA) and during the outcome year in the four matched cohort comparisons: (A) ICS ± SABA vs SABA, (B) LTRA ± SABA vs SABA, (C) LTRA vs ICS, and (D) EF-particle ICS vs fine-particle ICS. **Notes:** A wheezing/asthma attack was defined as an asthma-related ED attendance, an asthma-related hospital admission, or an OCS prescription coded for asthma or wheeze. EF: EF particle; fine: fine particle. **Abbreviations:** ED, emergency department; EF, extrafine; ICS, inhaled corticosteroid; LTRA, leukotriene receptor antagonist; OCS, oral corticosteroid; SABA, short-acting β-agonist.

See this image and copyright information in PMC

References

1. Bisgaard H, Szefler S. Prevalence of asthma-like symptoms in young children. Pediatr Pulmonol. 2007;42(8):723–728. - PubMed
1. Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ. Asthma and wheezing in the first six years of life. The Group Health Medical Associates. N Engl J Med. 1995;332(3):133–138. - PubMed
1. Uphoff EP, Bird PK, Antó JM, et al. Variations in the prevalence of childhood asthma and wheeze in MeDALL cohorts in Europe. ERJ Open Res. 2017;3(3) - PMC - PubMed
1. British Thoracic Society BTS National Paediatric Asthma Audit Summary Report (1–30 November 2015) 2016. [Accessed June 26, 2018]. Available from: https://www.brit-thoracic.org.uk/document-library/audit-and-quality-impr...
1. Zein JG, Udeh BL, Teague WG, et al. Impact of age and sex on outcomes and hospital cost of acute asthma in the United States, 2011-2012. PLoS One. 2016;11(6):e0157301. - PMC - PubMed

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Matched cohort study of therapeutic strategies to prevent preschool wheezing/asthma attacks

Collaborators

Affiliations

Matched cohort study of therapeutic strategies to prevent preschool wheezing/asthma attacks

Authors

Collaborators

Affiliations

Abstract

Conflict of interest statement

Figures

References

LinkOut - more resources

Full Text Sources